Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

1448956

USP

Mycophenolat-Mofetil

United States Pharmacopeia (USP) Reference Standard

Synonym(e):

(4E)-6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexensäure-2-(4-morpholinyl)-ethylester, RS 61443, TM-MMF

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C23H31NO7
CAS-Nummer:
128794-94-5
Molekulargewicht:
433.49
MDL-Nummer:
MFCD00867568
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329750505
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

mycophenolate

Hersteller/Markenname

USP

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

Lagertemp.

15-25°C

SMILES String

COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN3CCOCC3

InChI

1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+

InChIKey

RTGDFNSFWBGLEC-SYZQJQIISA-N

Angaben zum Gen

human ... IMPDH1(3614) , IMPDH2(3615)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Biochem./physiol. Wirkung

Mycophenolat-mofetil ist ein Pro-Pharmakon von Mycophenolsäure (Kat.-Nr. M5255), das durch unspezifische Esterase in vivo zur Stammsubstanz gespalten wird. Mycophenolsäure hemmt Inosinmonophosphat-Dehydrogenaseund ist ein wirksames immunsuppressives Mittel.

Hinweis zur Analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Sonstige Hinweise

Sales restrictions may apply.

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

Y0000489

Mycophenolat-Mofetil, European Pharmacopoeia (EP) Reference Standard

Y0000519

Mycophenolatmofetil für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard

1448967

Mycophenolatmofetil-verwandte Verbindung A, United States Pharmacopeia (USP) Reference Standard

1448978

Mycophenolatmofetil-verwandte Verbindung B, United States Pharmacopeia (USP) Reference Standard

1448989

Mycophenolatnatrium, United States Pharmacopeia (USP) Reference Standard

Y0002200

Mycophenolat für die Systemeignung, European Pharmacopoeia (EP) Reference Standard

PHR2776

Mycophenolat-Mofetil-verwandtes Präparat B, Pharmaceutical Secondary Standard; Certified Reference Material, pkg of 100 mg

PHR3211

Mycophenolat-Natrium, pharmaceutical secondary standard, certified reference material

Signalwort

Danger

Gefahreneinstufungen

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Repr. 1B - STOT RE 1

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 5

1 of 5

Mycophenolic acid solution 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

M-106

Mycophenolic acid solution

Teriflunomid ≥98% (HPLC)

Sigma-Aldrich

SML0936

Teriflunomid

Fumarsäure-dimethylester certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

Supelco

50744

Fumarsäure-dimethylester

Tacrolimus United States Pharmacopeia (USP) Reference Standard

USP

1642802

Tacrolimus

Rapamycin VETRANAL®, analytical standard

Supelco

37094

Rapamycin

A D Goralczyk et al.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 12(10), 2601-2607 (2012-07-21)
Liver transplant recipients are at high risk of developing acute and chronic renal failure. Moreover, introduction of the model for end-stage liver disease (MELD) score for primary allocation of liver grafts favors patients with pretransplant kidney dysfunction, which in turn
P Satwani et al.
Leukemia, 29(2), 448-455 (2014-06-19)
The outcome of children, adolescents and young adults (CAYA) with poor-risk recurrent/refractory lymphoma is dismal (⩽30%). To overcome this poor prognosis, we designed an approach to maximize an allogeneic graft vs lymphoma effect in the setting of low disease burden.
K Budde et al.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 14(12), 2796-2806 (2014-10-04)
This Phase III randomized trial examined efficacy and safety of a novel once-daily extended-release tacrolimus formulation (LCP-Tacro [LCPT]) versus twice-daily tacrolimus in de novo kidney transplantation. Primary efficacy end point was proportion of patients with treatment failure (death, graft failure
John Seal et al.
Transplantation, 99(3), 623-628 (2014-08-26)
There is a paucity of contemporary data describing the results of pancreas retransplantation (PRT). As a measure of utility, we wished to determine whether PRT could produce equivalent short-term and long-term recipient outcomes to primary pancreas after kidney (PAK) transplantation.
Andrew Bentall et al.
Transplantation, 98(10), 1089-1096 (2014-06-10)
ABO-incompatible kidney transplantations (ABOiKTxs) seem to have better long-term outcomes than positive crossmatch kidney transplantations (+XMKTxs). This study aimed to assess the differences in chronic injury on histologic findings on 1- and 5-year surveillance biopsies and the clinical outcomes in
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.